2025年1月7日 · Gpo-L-One is an iron chelator that binds to ferric ions (iron III) and forms a 3:1 (deferiprone:iron) stable complex and is then eliminated in the urine. Gpo-L-One is more selective for iron in which other metals such as zinc, copper, and aluminum have a …

Seventy-three pediatric patients with severe β thalassemias, age range 3.2-19 years, were recruited to a 1-year multicenter prospective, single arm, open label, dose escalating Phase III study of deferiprone to determine its clinical efficacy and safety. Sixty-four patients (87.6%) completed the study with good compliance (>94%).

2013年1月6日 · This is the first study to report the safety of GPO-L-ONE ® in a long-term exposure (up to 1 year) in patients with transfusion-dependent thalassemia. AEs of any given drug could be resulted from the nature of such compound or derived from the manufacturing's quality including product's purity and undesirable contaminations.

In this study, deferiprone (GPO-L-ONEVR) was further eval-uated as a monotherapy for its efficacy on body iron reduction and safety profile in transfusion dependent Thai thalassemia patients with iron overload.

Nonlawan Chueamuangphan Department of Medicine, Chiang Rai Hospital patients with thalassemia (Thal). Objective: To assess outcomes after deferiprone (GPO-L-ONE®) treatment of iron overload in alassemia patients. Materials and Methods: A prospective study was conducted in thalassemia patients at Chiang Rai Hospital, Chia

2023年6月26日 · Gpo-L-One monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or …

GPO-L-One Tablet is indicated for treatment of iron overload in patients with thalassaemia major when deferoxamine therapy is contraindicated or inadequate. GPO-L-One Tablet is given orally, 75 mg/kg body weight daily, in 2 to 4 divided doses.

Gpo-L-One® (Gpo-L-One) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Approval is based on a reduction in serum ferritin levels.

Gpo-L-One is used to treat people with transfusion-dependent, thalassemia (a blood disorder passed down through families that is characterized by anemia, fatigue, and short stature), as well as strangulated obstructive jaundice and secondary hemochromatosis due to …

TM วัุตถประสงค์ เพ ืู่้้่ อให ผปวยโรคโลหิตจางธาลัีี้ั สซ เมยไดรบยา GPO-L-ONE ขององค์การเภสัชกรรมอย่ั่ึ างท วถง ภายใต้สปสช.